Chk1 kinase inhibition was recently reported to increase sensitivity to gemcitabine in two p53 mutant NSCLC cell lines with either high (H1299) or low (H1993) Chk1 [25]. The gene discussed is CHEK1; the disease is non-small cell lung carcinoma.